CW January 2006
Volume 15Issue Number 1 January 2006 ISSN 10593802 Lower Thalidomide Dose Just as Effective, Better ToleratedWhile thalidomide?s (THL) (Thalomid, Celgene) effectiveness for patients with multiple myeloma has been demonstrated widely, some toxicities have been problematic. A study comparing a lower THL dose to the standard dose found the lower dose equally effective with reduced side effects.
Go to Previous Page Source & Additional Reading I. Yakoub-Agha et al., Hematol. J. 2002. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW January 2006Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
